Asabys Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Quibim, headquartered in Valencia, Spain, is a leader in whole-body medical imaging analysis, focusing on the integration of artificial intelligence in image processing. The company provides advanced solutions for extracting quantitative information from radiological images, which aids in the diagnosis of high-incidence illnesses and evaluates the effects of pharmacological treatments. Quibim Precision®, its comprehensive imaging ecosystem, is utilized by pharmaceutical companies and research teams worldwide for a variety of applications, including disease detection and monitoring treatment efficacy. By leveraging AI technology, Quibim enhances the ability to detect pathologies across all body parts and imaging modalities, ultimately contributing to improved health outcomes.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

MedLumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company develops integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method that offers detailed sectional information about tissue. MedLumics' radiofrequency cardiac ablation system provides real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation enhances procedural safety, reduces technical complexity, and lowers recurrence rates for patients undergoing treatment.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

XRHealth Ltd. is a medical technology company based in Tel Aviv, Israel, that specializes in developing virtual reality (VR) software solutions for healthcare. Founded in 2016, the company offers an array of products designed to enhance patient care and treatment outcomes. Its offerings include VRPhysio, a platform for virtual physical therapy; VRReliever, which helps manage pain through distraction; VRCogni, aimed at improving motor function in stroke and dementia patients; and VRPsyc, which provides exposure therapy for various mental health disorders. Additionally, VRCoordi is designed to aid coordination recovery in patients with Parkinson's, brain injuries, and autism. By integrating immersive technologies with licensed clinicians and advanced data analytics, XRHealth provides comprehensive telehealth services, allowing patients to access treatment from the comfort of their own homes.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Gradient Denervation Technologies is a medical device company based in Paris, France, founded in 2019. It specializes in the development of an endovascular catheter-based technology designed to treat pulmonary hypertension. The device focuses on performing pulmonary artery denervation, which aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics. This innovative approach offers a minimally invasive solution for managing pulmonary hypertension and is built upon prior research and intellectual property developed at Stanford University. The company aims to provide the healthcare sector with a device that delivers consistent and long-lasting results for patients suffering from this condition.

Orikine Bio is an innovative biotechnology company focused on developing tailored cytokine-based therapies for the treatment of autoimmune and inflammatory diseases. The company utilizes a proprietary platform to engineer cytokines with unique biological properties, aiming to provide transformative treatment options for patients suffering from immune-mediated disorders. By advancing the field of engineered cytokines, Orikine Bio seeks to create therapies that have the potential to significantly improve patient outcomes and enhance overall quality of life.

Nuage Therapeutics is a pharmaceutical company that specializes in developing selective and potent drugs targeting intrinsically disordered proteins, which are often challenging to address with traditional therapies. The company employs advanced techniques such as chemical biology and biomolecular condensation to create medications for difficult-to-treat conditions, including castration-resistant prostate cancer. By focusing on these disordered regions of proteins, Nuage Therapeutics aims to meet significant unmet medical needs and improve patient outcomes.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Amelia Virtual Care is a mental health technology company based in Barcelona and Mountain View that specializes in developing a comprehensive virtual reality platform for the treatment of various mental health disorders, including phobias, anxiety, and depression. With a team of over 60 employees, Amelia has delivered more than 200,000 VR therapy sessions globally, primarily focusing on the United States market. The company's platform is designed to enhance mental health treatment by providing professionals with a user-friendly control panel and complete VR equipment, facilitating effective therapy sessions. Recent financing and a new management team are set to accelerate Amelia's growth and enhance its commercial presence and clinical validation within the mental health sector.

Cara Care is a digital health platform focused on improving gut health for individuals with chronic gastrointestinal issues. It offers an app that enables patients to track their dietary habits, symptoms, and emotional states, facilitating a better understanding of their digestive health. By combining behavioral, microbial, and nutritional data, Cara Care empowers over 700,000 patients worldwide to take control of their health. The application allows users to customize their food choices and monitor symptoms such as pain and bloating, helping them identify patterns related to their conditions. This innovative approach goes beyond traditional treatment methods, providing a comprehensive tool for managing chronic digestive disorders in a convenient manner.

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

MedLumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company develops integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method that offers detailed sectional information about tissue. MedLumics' radiofrequency cardiac ablation system provides real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation enhances procedural safety, reduces technical complexity, and lowers recurrence rates for patients undergoing treatment.

Koa Health B.V., founded in 2018 and headquartered in Amsterdam, specializes in digital healthcare solutions aimed at enhancing mental well-being in the workplace. The company, which also has offices in Barcelona, the United States, and the United Kingdom, develops a range of applications, including the koa foundation, to support employees' mental health. Koa Health's offerings incorporate the latest clinical research and technology to provide accessible and personalized mental health support across various conditions. Its product suite includes Foundations for managing mild mental health issues, Perspectives for delivering standalone cognitive-behavioral therapy (CBT) for more serious cases, and Mindset, which offers supervised digital-first CBT for patients at elevated clinical risk. Additionally, Koa Health provides a library of evidence-based activities designed to address stress, sleep improvement, relaxation, positive thinking, and self-confidence, making it a comprehensive resource for mental health prevention, prediction, and treatment.

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

Origo Biopharma S.L. is a biotechnology company founded in 2017 and headquartered in San Cibrao das Viñas, Spain. The company focuses on the research and development of immunotherapeutic products aimed at treating severe diseases associated with TGF-β signaling dysfunction, including cancer and fibrosis. By developing organ-restricted drugs, Origo Biopharma seeks to address unmet medical needs in these areas, providing potential cures for debilitating health conditions.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Anaconda Biomed SL, founded in 2015 and headquartered in Barcelona, Spain, specializes in the development of innovative medical devices for the treatment of acute ischemic stroke. The company focuses on creating advanced neuro-thrombectomy systems, including the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system features a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever that expands to conform to the artery, allowing for the effective removal of blood clots without fragmentation. Anaconda Biomed aims to provide patients with rapid treatment options that significantly reduce the risk of fatality associated with strokes.

Cara Care is a digital health platform focused on improving gut health for individuals with chronic gastrointestinal issues. It offers an app that enables patients to track their dietary habits, symptoms, and emotional states, facilitating a better understanding of their digestive health. By combining behavioral, microbial, and nutritional data, Cara Care empowers over 700,000 patients worldwide to take control of their health. The application allows users to customize their food choices and monitor symptoms such as pain and bloating, helping them identify patterns related to their conditions. This innovative approach goes beyond traditional treatment methods, providing a comprehensive tool for managing chronic digestive disorders in a convenient manner.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Amelia Virtual Care is a mental health technology company based in Barcelona and Mountain View that specializes in developing a comprehensive virtual reality platform for the treatment of various mental health disorders, including phobias, anxiety, and depression. With a team of over 60 employees, Amelia has delivered more than 200,000 VR therapy sessions globally, primarily focusing on the United States market. The company's platform is designed to enhance mental health treatment by providing professionals with a user-friendly control panel and complete VR equipment, facilitating effective therapy sessions. Recent financing and a new management team are set to accelerate Amelia's growth and enhance its commercial presence and clinical validation within the mental health sector.